UroGen Pharma Ltd.
Financials
Valuation Metrics
UroGen Pharma Ltd.'s Market Cap is $2.11B. At end of 2025 it was $1.15B. Ranked #1977 of 3,121 in US market (top 63%), #751 of 1,463 on NASDAQ (top 51%), #132 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 50%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.11B | US#1,977/3,121 Sec#132/266 |
| Revenue | $189M | US#2,589/3,121 Sec#111/266 |
| Net Income | $-98M | US—/3,121 Sec—/266 |
| Total Assets | $253M | US#2,954/3,121 Sec#227/266 |
| Net Assets | $-132M | US#2,975/3,121 Sec#254/266 |
| Employees | 300 | US#2,420/3,121 Sec#110/266 |
| Value | ||
| P/S | 11.16x | US#2,720/3,121 Sec#117/266 |
| FCF Yield | -7.55% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROA | -38.65% | US#2,942/3,121 Sec#187/266 |
| Op. Margin | -35.32% | US#2,659/3,121 Sec#107/266 |
| Revenue Growth | 100.27% | US#99/3,121 Sec#36/266 |
| Financial Health | ||
| Total Debt | $196M | US#2,256/3,121 Sec#96/266 |
| FCF | $-159M | US#2,732/3,121 Sec#184/266 |
| Cash | $79M | US#2,355/3,121 Sec#193/266 |
| Current Ratio | 3.80x | US#609/3,121 Sec#168/266 |
| Performance | ||
| 1Y Return | 129.20% | US#117/3,121 Sec#46/266 |
| 1M Return | -14.00% | US#2,456/3,121 Sec#187/266 |
| From 52W High | -14.88% | US#1,003/3,121 Sec#68/266 |
| 1Y MDD | -42.22% | US#2,121/3,121 Sec#148/266 |
| Trading | ||
| Volume | 540,601 shares | US#1,760/3,121 Sec#186/266 |
| Trading Value | $24M | US#1,625/3,121 Sec#123/266 |
| Per Share | ||
| EPS | $-2.00 | US—/3,121 Sec—/266 |
| BPS | $-2.72 | US—/3,121 Sec—/266 |
Company Info
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.